These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 32511754)

  • 21. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.
    Ravat S; Rohatgi A; Kulkarni R; Jabeen SA; Patil B; Dash A; Malhotra M
    Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perampanel as monotherapy or first adjunctive therapy in pediatric and adult patients with epilepsy: the first United States-based phase IV open-label ELEVATE study.
    Punia V; Klein P; Mihaylova T; Biton V; Samad O; Ngo LY; Kumar D; Malhotra M
    J Neurol; 2024 Jul; 271(7):4587-4598. PubMed ID: 38730096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
    Steinhoff BJ; Patten A; Williams B; Malhotra M
    Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.
    French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F
    Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
    Singh K; Shah YD; Luciano D; Friedman D; Devinsky O; Kothare SV
    Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
    Tsai JJ; Ikeda A; Hong SB; Likasitwattanakul S; Dash A
    Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and safety of perampanel as early add-on treatment in patients with epilepsy and focal seizures in the routine clinical practice: Spain prospective study (PERADON).
    Abril Jaramillo J; Estévez María JC; Girón Úbeda JM; Vega López Ó; Calzado Rivas ME; Pérez Díaz H; García Martín G; Vila Herrero E; Chamorro-Muñoz M; Vázquez F; De la Fuente C; Redondo L; Peláez N; Santágueda P; Rodríguez Uranga JJ
    Epilepsy Behav; 2020 Jan; 102():106655. PubMed ID: 31812902
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
    Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
    Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
    [No Abstract]   [Full Text] [Related]  

  • 29. Perampanel outcomes at different stages of treatment in people with focal and generalized epilepsy treated in clinical practice: Evidence from the PERMIT study.
    Liguori C; Santamarina E; Strzelczyk A; Rodríguez-Uranga JJ; Shankar R; Rodríguez-Osorio X; Auvin S; Bonanni P; Trinka E; McMurray R; Sáinz-Fuertes R; Villanueva V
    Front Neurol; 2023; 14():1120150. PubMed ID: 37064177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of perampanel monotherapy in Chinese patients with focal-onset seizures: A single-center, prospective, real-world observational study.
    Ma H; Zhu H; Chen F; Yang Y; Qu X; Xu H; Yang L; Zhang R
    Epilepsia Open; 2023 Dec; 8(4):1474-1483. PubMed ID: 37661647
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (aged 4 to <12 years) with inadequately controlled focal-onset seizures: Japanese subgroup analysis.
    Omatsu H; Watanabe T; Kira R; Ishiba K; Patten A; Takase T; Ngo LY
    Seizure; 2023 Aug; 110():109-116. PubMed ID: 37336055
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First add-on perampanel for focal-onset seizures: An open-label, prospective study.
    Kim JH; Kim DW; Lee SK; Seo DW; Lee JW; Park HJ; Lee SA
    Acta Neurol Scand; 2020 Feb; 141(2):132-140. PubMed ID: 31745975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
    Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
    Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and tolerability of perampanel in children and adolescents with refractory epilepsies-An Italian observational multicenter study.
    De Liso P; Vigevano F; Specchio N; De Palma L; Bonanni P; Osanni E; Coppola G; Parisi P; Grosso S; Verrotti A; Spalice A; Nicita F; Zamponi N; Siliquini S; Giordano L; Martelli P; Guerrini R; Rosati A; Ilvento L; Belcastro V; Striano P; Vari MS; Capovilla G; Beccaria F; Bruni O; Luchetti A; Gobbi G; Russo A; Pruna D; Tozzi AE; Cusmai R
    Epilepsy Res; 2016 Nov; 127():93-100. PubMed ID: 27568598
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical outcomes of eslicarbazepine acetate monotherapy for focal-onset seizures: A multicenter audit.
    Giráldez BG; Garamendi-Ruiz I; Zurita J; García A; Querol R; Campos D; Cabeza-Alvarez C; Serrano P; López-González FJ; Molins A; Serratosa JM
    Acta Neurol Scand; 2019 Dec; 140(6):422-428. PubMed ID: 31498422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
    Tsai JJ; Wu T; Leung H; Desudchit T; Tiamkao S; Lim KS; Dash A
    Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perampanel effectiveness and safety as early add-on treatment for focal-onset seizures: PEREAGAL study.
    Rodríguez-Osorio X; Lema-Facal T; Rubio-Nazábal E; Castro-Vilanova MD; Pato-Pato A; Abella-Corral J; Corredera E; López-Ferreiro A; Puy-Núñez A; López-González FJ
    Epilepsy Res; 2021 May; 172():106570. PubMed ID: 33621770
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: A prospective study evaluating efficacy, tolerability, and behavior.
    Zhou R; Qu R; Liu M; Huang DP; Zhou JY; Chen Y; Chen XQ
    Epilepsy Behav; 2023 Sep; 146():109353. PubMed ID: 37481960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
    Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
    Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oxcarbazepine oral suspension in young pediatric patients with partial seizures and/or generalized tonic-clonic seizures in routine clinical practice in China: a prospective observational study.
    Qin J; Wang Y; Huang XF; Zhang YQ; Fang F; Chen YB; Lin ZD; Deng YC; Yin F; Jiang L; Wu Y; Hu XS
    World J Pediatr; 2018 Jun; 14(3):280-289. PubMed ID: 29464579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.